Bloom Health Partners (BLMH:CSE) has come out with some massive expectations for the 2022 fiscal year. In recent guidance, $BLMH.C stated it anticipates 2022 revenues of CAD $25M - $28M. Given the company’s current market capitalization of $15.38M, it is needless to say that these numbers are absolutely bonkers.
Given $BLMH.C’s current P/S ratio of 1.57 based on reported 2021 revenues of $9.8 million, If $BLMH is able to capture the revenue they project the company would be valued at a price of $39.234M - $43.96 million. At current dilution, that would price shares at $1.0 - $1.12. However, I would expect a company reporting this much speculative under-evaluation to see a steep increase in trading volume, driving the value of the stock even higher.
The company expects continued growth from the COVID-19 testing side of its Operation Health Services business to provide the main drive for revenue.
Shares of $BLMH.C are currently up 9.72% today, and with this guidance, I anticipate these gains will start to accelerate. $BLMH.C is currently trading at $.395 at an MCAP of $15.38 million.
https://ceo.ca/@newsfile/bloom-health-partners-provides-guidance-and-corporate